Skip to main content

Table 1 Demographic characteristics of subjects

From: Comparison of inflammation, arterial stiffness and traditional cardiovascular risk factors between rheumatoid arthritis and inflammatory bowel disease

 

Control (n = 73)

RA (n = 43)

IBD (n = 42)

Age, y

51 ± 10

55 ± 11

50 ± 10

Male, %

46

51

45

SBP, mmHg

118 ± 14

126 ± 13*

125 ± 17

DBP, mmHg

67 ± 10

74 ± 9**

74 ± 10**

Body mass index, kg/m2

25.6 ± 3.8

28.1 ± 5.8*

26.9 ± 6.1

Waist, cm

88.2 ± 11.7

96.0 ± 15.5*

92.3 ± 14.3

Diabetes, %

10

14

10

Total cholesterol, mmol/L

5.45 ± 0.86

5.30 ± 1.13

5.23 ± 1.20

LDL-C, mmol/L

3.45 ± 0.81

3.25 ± 1.12

3.19 ± 1.15

HDL-C, mmol/L

1.50 ± 0.33

1.44 ± 0.37

1.46 ± 0.45

Triglycerides, mmol/L

0.9 (0.7, 1.4)

1.30 (0.9, 1.6)**

1.0 (0.7, 1.7)

Never/ex/current smokers, %

77/19/4

40/34/26***

28/52/20***

Anti-HT treatment, %

8

37***

9##

LLT, %

4

11

5

FBS, mmol/L

4.8 (4.5, 5.2)

4.9 (4.5, 5.4)

4.6 (4.4, 5.2)

FRS

2.0 (0, 4.5)

4.0 (1.0, 12.0)**

2.0 (0, 8.0)

  1. Results were expressed as mean ± SD, or percentage or median (25, 75 percentile). *,**,*** vs. control p < 0.05, <0.01, <0.001, respectively, ##, vs. RA p < 0.01. Anti-HT treatment: anti-hypertensive treatment; ex-smoker: prior smokers who have not smoked in the last 12 months; DBP: diastolic blood pressure; FBS: fasting blood sugar; FRS: Framingham Risk Score; HDL-C: high-density lipoprotein cholesterol; IBD: inflammatory bowel disease; LDL-C: low-density lipoprotein cholesterol; LLT: lipid-lowering therapy; RA: rheumatoid arthritis; SBP: systolic blood pressure.
Back to article page

Journal of Inflammation

ISSN: 1476-9255

Contact us